In vivo studies showed that specific deletion of myeloid cell Gpx4 in mice exhibited SLE-like clinical manifestations, which could be alleviated by treatment with liproxstatin-1, an ferroptosis inhibitor, and attenuated disease progression. Here, GPX4 is linked to systemic lupus erythematosus.